![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1 Infected Subjects
|
|
|
ID Week 2019
October 2-6, 2019; Washington, DC
Reported by Jules Levin
Kelong Han,1Mark Baker,2Parul Patel,2David Margolis,2William Spreen,2Katy Moore,2Susan L. Ford3
1GlaxoSmithKline, Collegeville, PA; 2ViiV Healthcare, Research Triangle Park, NC; 3GlaxoSmithKline, Research Triangle Park, NC
![1202191](../images/120219/120219-10/1202191.gif)
![1202192](../images/120219/120219-10/1202192.gif)
![1202193](../images/120219/120219-10/1202193.gif)
![1202194](../images/120219/120219-10/1202194.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|